Q2 delivered strong revenue growth and profitability, driven by operational efficiency and the launch of apotea.no in Norway. Inventory and CapEx rose with the Varberg center, but the balance sheet remains robust. Growth initiatives and Rx expansion are key priorities.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.